2D- and 3D-cultures of human trabecular meshwork cells: A preliminary assessment of an in vitro model for glaucoma study.
Apoptosis
/ drug effects
Cell Culture Techniques
Cell Respiration
/ drug effects
Cytokines
/ metabolism
Gene Expression Regulation
/ drug effects
Glaucoma
/ pathology
Humans
Hydrogen Peroxide
/ pharmacology
Mitochondria
/ drug effects
NF-kappa B
/ genetics
Oxidative Stress
/ drug effects
Reactive Oxygen Species
/ metabolism
Trabecular Meshwork
/ cytology
Transcriptional Activation
/ drug effects
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
22
05
2019
accepted:
19
08
2019
entrez:
7
9
2019
pubmed:
7
9
2019
medline:
7
3
2020
Statut:
epublish
Résumé
A physiologically relevant in vitro human-based model could be the 'gold standard' to clarify the pathological steps involved in glaucoma onset. In this regard, human 3D cultures may represent an excellent starting point to achieve this goal. Indeed, the 3D matrix allows to re-create the in vivo-like tissue architecture, maintaining its functionality and cellular behaviour, compared to the 2D model. Thus, we propose a comparison between the 2D and 3D in vitro models of human trabecular meshwork cells in terms of cellular responses after chronic stress exposure. Our results showed that 3D-cells are more sensitive to intracellular reactive oxidative specie production induced by hydrogen peroxide treatment, compared to 2D cultures. Additionally, in 3D cultures a more accurate regulation of the apoptosis trigger and cell adaptation mechanisms was detected than in 2D models. In line with these findings, the 3D-HTMC model shows the ability to better mimic the in vivo cell behaviour in adaptive responses to chronic oxidative stress than 2D.
Identifiants
pubmed: 31490976
doi: 10.1371/journal.pone.0221942
pii: PONE-D-19-13032
pmc: PMC6731014
doi:
Substances chimiques
Cytokines
0
NF-kappa B
0
Reactive Oxygen Species
0
Hydrogen Peroxide
BBX060AN9V
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0221942Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Cell Biol. 1999 May 17;145(4):757-67
pubmed: 10330404
Free Radic Biol Med. 1999 Sep;27(5-6):612-6
pubmed: 10490282
Hum Genet. 2000 Nov;107(5):494-8
pubmed: 11140948
Nat Med. 2001 Mar;7(3):304-9
pubmed: 11231628
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
pubmed: 12184808
Biochim Biophys Acta. 2006 Aug;1758(8):994-1003
pubmed: 16566894
Nature. 2006 May 25;441(7092):431-6
pubmed: 16724054
Curr Cancer Drug Targets. 2009 Jun;9(4):451-68
pubmed: 19519315
Free Radic Biol Med. 2010 Apr 15;48(8):1064-70
pubmed: 20100568
Arch Ophthalmol. 2011 Jan;129(1):48-55
pubmed: 21220628
Am J Pathol. 2011 Jan;178(1):26-31
pubmed: 21224039
Biol Reprod. 2011 Aug;85(2):417-24
pubmed: 21566000
PLoS One. 2012;7(2):e31340
pubmed: 22319624
J Biomed Biotechnol. 2012;2012:692609
pubmed: 22665989
Cell Biochem Funct. 2014 Apr;32(3):217-28
pubmed: 23963693
J Cell Mol Med. 2013 Dec;17(12):1619-31
pubmed: 24118792
PLoS One. 2013 Oct 04;8(10):e76373
pubmed: 24124550
Cell Mol Life Sci. 2014 Jun;71(12):2197-218
pubmed: 24142347
J Anat. 2015 Dec;227(6):746-56
pubmed: 25411113
Oncol Rep. 2015 Apr;33(4):1837-43
pubmed: 25634491
Cell Biochem Biophys. 2015 Jul;72(3):777-82
pubmed: 25663505
Biomed Mater. 2015 Mar 16;10(3):034002
pubmed: 25775166
Brain Res Bull. 2015 Aug;117:1-9
pubmed: 26073842
Biosci Rep. 2015 May 07;35(3):null
pubmed: 26182370
J Cell Physiol. 2016 Sep;231(9):1876-93
pubmed: 26754581
Elife. 2016 Jan 14;5:e09100
pubmed: 26765569
Invest Ophthalmol Vis Sci. 2016 Apr 1;57(4):2344-54
pubmed: 27127934
Ageing Res Rev. 2016 Aug;29:26-41
pubmed: 27242026
Ophthalmic Res. 2017;57(2):77-86
pubmed: 27618367
J Cell Sci. 2017 Jan 1;130(1):203-218
pubmed: 27663511
Drug Discov Today. 2017 Feb;22(2):327-339
pubmed: 27989722
Exp Eye Res. 2017 Feb;155:91-98
pubmed: 28153738
Biomacromolecules. 2017 Mar 13;18(3):709-718
pubmed: 28157290
Invest Ophthalmol Vis Sci. 2017 Dec 1;58(14):6113-6122
pubmed: 29222553
Exp Eye Res. 2018 Jun;171:164-173
pubmed: 29526795
Biomicrofluidics. 2018 May 16;12(4):042204
pubmed: 29861815
Acta Biomater. 2018 Jul 15;75:200-212
pubmed: 29864516
Int J Mol Med. 2019 Feb;43(2):671-681
pubmed: 30483726
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Oncogene. 1996 Aug 15;13(4):665-75
pubmed: 8761287
Cancer Res. 1997 Jul 1;57(13):2687-93
pubmed: 9205078